Acetylcholine

Other Names

(2-acetoxyethyl)trimethylammonium2-(acetyloxy)-N,N,N-trimethylethanaminium2-Acetoxy-N,N,N-trimethylethanaminium2-acetoxyethyl-trimethyl-ammonium2-Acetoxyethyltrimethylammonium2-acetyloxyethyl(trimethyl)ammonium2-acetyloxyethyl(trimethyl)azaniumAcetyl cholineAcetyl choline cationAcetyl choline ionacetylcholine acetateacetylcholine bromideAcetylcholine Cationacetylcholine chlorideacetylcholine iodideAcetylcholine(1+)AcetylcholiniumAChcholine acetatecholine, acetyl-Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-O-AcetylcholineVagusstoff[2-(acetyloxy)ethyl]trimethylazanium

Synopsis

Acetylcholine: Comprehensive Reference Article

1. Identity and Chemical Characterization

Names and Chemical Structure

Acetylcholine (abbreviated ACh) is a low-molecular-weight organic cation classified as a quaternary ammonium compound. The name "acetylcholine" is derived from its chemical structure, as it is an ester of acetic acid and choline. Its IUPAC name is 2-(acetyloxy)-N,N,N-trimethylethan-1-aminium. Unlike most subjects of dietary-supplement articles, acetylcholine itself is not directly available as an oral supplement; acetylcholine is not available as a dietary supplement, but its levels can be indirectly raised through choline intake — a precursor to acetylcholine — as well as supplements that inhibit acetylcholine breakdown.

Endogenous Origin and Natural Sources

Acetylcholine is a neurochemical that has a wide variety of functions in the brain and other organ systems of the body. Specifically, it is a neurotransmitter that acts as a chemical message that is released by neurons and allows them to communicate with one another and other specialized cells such as myocytes and cells found in glandular tissues.

Acetylcholine is synthesized in nerve terminals from acetyl coenzyme A (acetyl CoA, which is synthesized from glucose) and choline, in a reaction catalyzed by choline acetyltransferase (CAT). The rate-limiting steps in ACh synthesis are the availability of choline and acetyl-CoA.

Choline is a water-soluble B-group vitamin, which humans must consume through their diet to remain healthy. Meat, eggs, and yeast extract are great sources of choline, an essential component of cell membranes and also the precursor of the neurotransmitter acetylcholine. Choline is a precursor of different metabolites including the neurotransmitter acetylcholine (ACh), the membrane phospholipids phosphatidylcholine (PC) and sphingomyelin, and the methyl donor betaine. Choline can be obtained from the diet and via de novo biosynthesis from the methylation of phosphatidylethanolamine (PE) to PC.

Common Forms and Supplement Preparations

Because acetylcholine does not cross the blood–brain barrier when taken orally, supplementation strategies focus on delivering choline-containing precursors. The main preclinical and clinical investigations have assessed the effects of different forms of choline supplementation currently available, including choline alfoscerate (C₈H₂₀NO₆P), also known as alpha-glycerophosphocholine (α-GPC, or GPC), choline bitartrate, lecithin, and citicoline, which are cholinergic compounds and precursors of acetylcholine. Key forms include:

Choline bitartrate — a salt form of choline commonly used in dietary supplements and studied in cognitive research.
Alpha-GPC (choline alfoscerate) — choline alphoscerate (alpha-glyceryl-phosphorylcholine, alpha-GPC) is a semisynthetic derivative of phosphatidylcholine with central parasympathomimetic action.
Citicoline (CDP-choline) — citicoline is a safe and very well-tolerated form of choline with good brain bioavailability. It is a precursor in the synthesis of phosphatidylcholine, a major component of biological membranes, and its production is a rate-limiting step in the biosynthesis of cellular phospholipids.
Lecithin (phosphatidylcholine) — a phospholipid found naturally in egg yolks, soybeans, and other foods, widely used as a dietary supplement and food additive.

The US Food and Drug Administration (FDA) identified choline as an essential nutrient in 1998. The National Academy of Medicine (NAM) of the USA and the European Food Safety Authority (EFSA) both specified adequate intake (AI) values for choline.

2. Traditional and Historical Use

Scientific Discovery — the Modern Historical Record

Acetylcholine does not feature in traditional herbal or botanical medicine under this name, as it was unknown until the early twentieth century. Its history is therefore primarily a scientific history rather than a tradition of human medicinal use.

Acetylcholine, the first neurotransmitter discovered, was originally described as "vagus stuff" by Otto Loewi because of its ability to mimic the electrical stimulation of the vagus nerve. In that famous experiment, Loewi placed two beating frog hearts, each in its own perfusion chamber — one preparation had the vagus nerve intact, while the other was denervated. He stimulated the vagus nerve supplying the first heart, causing it to beat more slowly. When Loewi applied the perfusate of the first heart to the second heart, it too slowed down, as if its vagus nerve had been stimulated as well. He named the inhibitory factor "vagusstoff," which is known today as acetylcholine.

In 1936, Sir Henry Dale of London and Professor Otto Loewi from Graz shared the Nobel Prize in Physiology or Medicine for their work on chemical neurotransmission. Dale's work extended from his discovery of naturally occurring acetylcholine in 1913, through to evidence of its role as a neurotransmitter at autonomic ganglia, post-ganglionic parasympathetic nerve terminals, and the neuromuscular junction.

In 1914, Henry Dale found that acetylcholine generated stimuli in part of the nervous system — the parasympathetic nervous system — which has a dampening effect on heart activity and other functions. After Otto Loewi demonstrated acetylcholine's function as a messenger between nerves and organs, Dale and other researchers refined the understanding of acetylcholine's role in the nervous system.

Traditional Use of Choline-Rich Foods

While acetylcholine as a molecule was unknown to premodern cultures, foods rich in choline — its dietary precursor — have featured in traditional diets globally for millennia. Eggs, organ meats such as liver, fish, and dairy are ancient dietary staples that provide choline. Choline is converted into a neurotransmitter called acetylcholine, which helps muscles to contract, activates pain responses, and plays a role in brain functions of memory and thinking. Medicinal traditions including Traditional Chinese Medicine and Ayurveda employed organ meats and egg-based preparations for purposes consistent with brain and memory support, although these traditions did not identify choline or acetylcholine as the active agents.

3. Key Constituents and Active Compounds

Choline: The Primary Dietary Precursor

Choline is an important nutrient essential for proper functioning of liver, muscle, and brain. It is a main constituent of cell and organelle membranes and plays a vital role in numerous physiological processes including signal transduction, DNA and histone methylation, and nerve myelination. It is a precursor for the widely distributed neurotransmitter acetylcholine, and it is a precursor for choline-phospholipids, which play a vital role in the regulation of transmembrane signaling. Only a small fraction of dietary choline is acetylated, catalyzed by the activity of choline acetyltransferase.

Acetyl-CoA and the Synthesis Pathway

In the presynaptic terminal, acetylcholine is synthesized from acetyl coenzyme A (acetyl CoA) and choline via the enzyme choline acetyltransferase (ChAT). The presence of ChAT in a neuron is used as a biochemical marker for neurons that produce acetylcholine. Acetylcholine is packaged into small vesicles for storage in the terminal via the vesicular acetylcholine transporter (VAChT), a protein found in the synaptic vesicle membrane.

Degradation: Acetylcholinesterase

Following depolarization, ACh undergoes exocytosis, reaching the synaptic cleft, where it can bind its receptors, including muscarinic and nicotinic receptors. ACh present at the synaptic cleft is promptly hydrolyzed by the enzyme acetylcholinesterase (AChE), forming acetate and choline, which is recycled into the presynaptic nerve terminal by the high-affinity choline transporter (CHT1).

Receptor Subtypes

The cholinergic receptors subdivide into nicotinic and muscarinic receptors, named after separate activating ligands that contributed to their study. Nicotinic receptors are responsive to the agonist nicotine, while muscarinic receptors are responsive to muscarine. The two receptors differ in function as ionotropic ligand-gated and G-protein-coupled receptors, respectively.

Nicotinic receptors: The nicotinic receptor has two binding sites for acetylcholine. When acetylcholine is bound to both sites on the receptor, the pore of the channel opens to allow movement of both sodium and potassium. This ionotropic receptor is an example of a direct mechanism of action, due to the fact that the receptor and the channel are located on the same protein. The properties of the receptors cause more sodium to enter than potassium leaves, ultimately causing the membrane to depolarize. Thus, nicotinic receptors are always excitatory (produce EPSPs) and cause depolarization of the postsynaptic cell.

Muscarinic receptors: Muscarinic receptors are G-coupled protein receptors involved in the parasympathetic nervous system. The response of muscarinic receptors may be excitatory or inhibitory. They do not affect skeletal muscles, but do influence the activity of smooth muscle, exocrine glands, and the cardiac conduction system. Five muscarinic receptor subtypes (M1–M5) have been described; M2 receptors, when activated, inhibit sympathetic influence on the heart, reducing contractility and reducing firing from the sinoatrial node, causing an overall decrease in heart rate. M3 receptors are present in smooth muscle structures, such as the bronchi, gastrointestinal tract, pupils, and blood vessels.

4. Mechanisms of Action

Neuromuscular Junction

While ACh operates as a neurotransmitter in many parts of the body, it is most commonly associated with the neuromuscular junction. The neuromuscular junction is where motor neurons located in the ventral spinal cord synapse with muscles in the body to activate them. ACh has excitatory actions at the neuromuscular junction, at autonomic ganglia, at certain glandular tissues, and in the CNS. It has inhibitory actions at certain smooth muscles and at cardiac muscle.

Autonomic Nervous System

In the autonomic nervous system, acetylcholine (ACh) is the neurotransmitter in the preganglionic sympathetic and parasympathetic neurons. ACh is also the neurotransmitter at the adrenal medulla and serves as the neurotransmitter at all the parasympathetically innervated organs.

Central Nervous System Neuromodulation

The diverse effects of acetylcholine depend on the site of release, the receptor subtypes, and the target neuronal population; a common theme is that acetylcholine potentiates behaviors that are adaptive to environmental stimuli and decreases responses to ongoing stimuli that do not require immediate action. The ability of acetylcholine to coordinate the response of neuronal networks in many brain areas makes cholinergic modulation an essential mechanism underlying complex behaviors.

Cardiovascular Effects

In the cardiovascular system, ACh via muscarinic receptors determines generalized vasodilation; decrease in heart rate (negative chronotropic effect); reduction of cardiac contraction force (negative inotropic effect); and decrease in the speed of conduction in the specialized tissue of the sinoatrial and atrioventricular nodes (negative dromotropic effect).

Cholinergic Anti-Inflammatory Pathway

Studies have uncovered a mechanism by which the inflammatory process can be regulated by activity of the parasympathetic nervous system. More specifically, efferent signals carried by the vagus nerve via acetylcholine can modulate the activity of resident macrophages and attenuate local and systemic inflammation — this regulatory activity has been termed "the cholinergic anti-inflammatory pathway." The vagus nerve is finely branched, innervating several major organ systems including the liver, heart, spleen, and gastrointestinal tract.

CD4+ T lymphocytes expressing the beta-2 adrenaline receptor uptake noradrenaline and release acetylcholine. Acetylcholine inhibits the production of proinflammatory cytokines in macrophages expressing the α7nAChR receptor (α7 nicotinic acetylcholine receptors). It significantly attenuates the production of the pro-inflammatory cytokines TNFα, interleukin-1β (IL-1β), IL-6, and IL-18.

Role in Sleep

Cholinergic neurotransmission at the CNS level is thought to regulate sleep, wakefulness, and memory. Animal research has further characterized the temporal relationship between ACh and sleep stages: low acetylcholine level during NREM sleep contributes to the consolidation of motor memory.

5. Body Systems and Health Areas

Central Nervous System — Cognition, Learning, and Memory

Although the neurodegeneration occurring in Alzheimer's disease affects multiple neurotransmitters, the cholinergic system has received the greatest attention. Acetylcholine is fundamental to mnemonic function, assisting in the septal hippocampal pathway and facilitating cortical activation. ACh plays a role in synaptic plasticity, including learning and short-term memory.

Alzheimer's Disease and the Cholinergic Hypothesis

The cholinergic hypothesis posits a central role for acetylcholine (ACh) deficiency in Alzheimer's disease (AD). Basal forebrain cholinergic projections innervate the neocortex and hippocampus — regions essential for learning, memory, and higher-order cognition. One of the earliest pathological events in AD is the degeneration of ACh-synthesizing neurons in the subcortical nuclei of the human basal forebrain. The loss of cholinergic function in AD is correlated with the density of histopathological markers of AD, the severity of cognitive dysfunction, and disease duration.

People with Alzheimer's disease have lower levels of the enzyme that converts choline into acetylcholine in the brain. This reduces acetylcholine's neuromodulatory influence on brain structures, and use of acetylcholinesterase inhibitors — to enhance ACh levels — remains a first-line treatment for Alzheimer's disease.

Neuromuscular System

Involvement of the muscle-type nicotinic acetylcholine receptors in diseases became clear with myasthenia gravis, while neuronal nAChRs are considered as drug targets against nicotine dependence and neurodegenerative diseases.

Autonomic / Cardiovascular System

Acetylcholine stimulation of the parasympathetic nervous system helps contract smooth muscles, dilate blood vessels, increase secretions, and slow the heart rate.

Gastrointestinal System

Muscarinic receptors are involved in peristalsis, micturition, bronchoconstriction, and several other parasympathetic reactions. Cholinergic signals also control GI inflammation and metabolic disease manifestations in experimental postoperative ileus, inflammatory bowel disease (IBD), and ischemia and reperfusion injury. A functional cooperation between the efferent vagus nerve and the splenic nerve, with the release of acetylcholine from a subset of T cells containing choline acetyltransferase, plays a major mediating role in the inflammatory reflex.

Immune System

The anti-inflammatory reflex reduces CD11b expression on neutrophils, stimulates the release of pro-resolving mediators (SPMs), and decreases antibody secretion and migration of B lymphocytes. In the intestine, ACh stimulates antigen-presenting cells, through muscarinic receptors, to favor the maintenance of regulatory T cells.

Developmental Biology

Acetylcholine is found in the first moments of developing the ectodermal system (neural plate), as its action is fundamental for the differentiation of neural cells. The neurotransmitter acts as a morphogen. The demand for choline increases particularly during pregnancy inasmuch as it is important for placental function, fetal growth, and brain development.

6. Scientific Evidence by Area of Use

6.1 Cognitive Function and Memory in Healthy Adults

Choline is a dietary component and precursor of acetylcholine, a crucial neurotransmitter for memory-related brain functions. In two double-blind, placebo-controlled cross-over experiments, investigators studied whether the food supplement choline bitartrate improved declarative memory and working memory in healthy, young students one to two hours after supplementation. The study found no acute benefit, representing evidence that short-term choline bitartrate supplementation does not immediately enhance memory in healthy young adults. Although some observational studies have found that higher intakes of choline are associated with higher levels of cognitive function like memory, clinical trials have not found that choline supplementation significantly improves these cognitive measures.

Evidence strength: For healthy young adults, evidence of benefit from choline or ACh-precursor supplementation is weak. Observational associations exist but have not been replicated in controlled trials.

6.2 Cognitive Impairment and Alzheimer's Disease — Alpha-GPC

Choline alphoscerate (alpha-glyceryl-phosphorylcholine, αGPC) is a choline-containing phospholipid that is often used as a dietary supplement. Choline passes through the blood–brain barrier, which results in increased choline levels. Choline is a precursor of acetylcholine, an essential neurotransmitter for memory and learning.

A 2024 multicenter, randomized, double-blind, placebo-controlled trial enrolled 100 subjects with amnestic mild cognitive impairment (MCI). After 12 weeks of αGPC treatment (600 mg), the ADAS-cog score decreased by 2.34 points, which was significantly greater than the change observed in the placebo group. No serious adverse events were reported, and no study subjects discontinued the intervention.

A recent review concluded that αGPC, either alone or in combination with the cholinesterase inhibitor donepezil, can improve cognition, functional, and behavioral status in patients with AD and other neurological dementia disorders. A 2023 Frontiers systematic review and meta-analysis reported: Alpha-GPC demonstrated statistically significant improvements over citicoline in overall clinical conditions of dementia patients, as measured by the SCAG global scale score after 90 days of treatment. Additionally, the review demonstrated that alpha-GPC led to significant improvements in non-cognitive symptoms compared to citicoline, as assessed by SCAG scores, including greater reductions in interpersonal difficulties, affective disturbances, and apathy.

For Alzheimer's trials, patients have taken 400 mg three times per day (1,200 mg total).

Evidence strength: Moderate for patients with cognitive impairment or Alzheimer's disease. Multiple controlled trials show statistically significant improvements in cognitive scales. Studies are frequently conducted in populations already taking acetylcholinesterase inhibitors, limiting assessment of alpha-GPC as a standalone therapy. Independent replication in large, long-term RCTs is still needed.

6.3 Cognitive Impairment and Dementia — Citicoline (CDP-Choline)

Citicoline is considered to be the most brain-bioavailable form of choline, an essential nutrient for brain function, and has been clinically tested primarily for neurodegenerative conditions including stroke, dementia, traumatic brain injury, and glaucoma. The effects of citicoline appear to be minor compared to standard-of-care treatment for these conditions, and it may be most effective as an adjunct treatment.

The IDEALE study was an open multicenter Italian study assessing the effectiveness and safety of oral citicoline in elderly people with mild vascular cognitive impairment, performed in 349 patients. The active (citicoline) group was composed of 265 patients of mean age 79.9 ± 7.8 years. The study showed that citicoline is effective and safe in the treatment of mild vascular cognitive impairment. The treated group showed improvement in MMSE scores, with an increase of 0.5 points over the course of the study.

Animal studies suggest that CDP-choline may protect cell membranes by accelerating resynthesis of phospholipids. CDP-choline may also attenuate the progression of ischemic cell damage by suppressing the release of free fatty acids, and has been shown to increase cerebral metabolism and noradrenaline and dopamine levels in the central nervous system.

Doses range from 250–1,000 mg/day. Trials in healthy adults typically used doses of 500 mg/day, while trials in patients with neurodegenerative disease typically used doses of 1,000 mg/day.

Evidence strength: Moderate but mixed. The Cochrane Database has reviewed CDP-choline for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly (Fioravanti and Yanagi, 2004). While clinical trials show some benefit on cognitive scales, there is no evidence to date that citicoline can prevent dementia.

6.4 Acute Ischemic Stroke — Citicoline

One pivotal study comprised a randomized (three doses of citicoline to one placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and continued orally for 6 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference favoring citicoline was reported for functional outcome.

As a multimodal drug, CDP-choline exhibits comprehensive neuroprotective effects and has demonstrated neuroprotection and neurogenesis in various central nervous system experimental and clinical conditions, including acute and chronic ischemic stroke, intracranial hemorrhage, Parkinson's disease, and Alzheimer's disease.

Evidence strength: Preliminary to moderate. Multiple trials have tested citicoline in stroke; the compound appears safe and possibly beneficial, but large definitive trials have produced mixed results and regulatory approvals for stroke vary by country.

6.5 Choline Supplementation in Pregnancy and Neurodevelopment

Choline supplementation of the mothers of unborn rats, as well as rat pups during the first month of life, led to improved performance in spatial memory tests months after choline supplementation had been discontinued. Human data are less definitive. Randomized controlled trials of choline supplementation throughout the periconceptional period would be needed to determine whether choline has a protective effect against neural tube defects.

Adequate dietary intake of choline during pregnancy supports proper fetal development, and throughout life supports brain, liver, and muscle functions, while choline deficiency is linked to disease states like fatty liver.

Evidence strength: Preliminary in humans; stronger in animal models. Animal data are compelling; controlled trials in humans are limited.

6.6 Memory Enhancement in Aging Populations — Choline Blood Levels

Research in animals and humans suggests that higher intakes of choline, a precursor to acetylcholine, may boost memory in people with memory issues. A study in 2,195 participants aged 70–74 found that those with higher blood levels of choline performed significantly better in memory and learning tasks than those with low levels.

Evidence strength: Observational; requires confirmation in prospective interventional trials.

6.7 Anxiety and Mental Health

An observational study with over 5,900 participants found that low blood levels of choline were linked to a higher risk of anxiety, though it did not find a link between blood choline levels and depression. Another study in 50 people with depression observed that people who took 200 mg of citicoline daily for 6 weeks alongside citalopram had less severe depressive symptoms than those who only took their depression medications.

Evidence strength: Preliminary and largely observational. The citicoline + citalopram study was small (n=50) and requires replication.

6.8 Liver Function

When supplemental choline (in the form of lecithin) was administered during parenteral nutrition in humans, plasma choline levels returned to normal, and the incidence of hepatic dysfunction and steatosis diminished. Subjects treated with placebo did not get better. Choline deficiency can cause serious medical conditions such as premature birth, cystic fibrosis, and hepato-steatosis.

Evidence strength: Moderate for the specific context of choline repletion in patients on parenteral nutrition with confirmed deficiency. Evidence for benefit in otherwise healthy individuals is limited.

7. Dosage Forms and Reported Dosages

Dietary Adequate Intake (AI) for Choline

The primary criterion used to estimate the Adequate Intake (AI) for choline is the prevention of liver damage as assessed by measuring serum alanine aminotransferase levels. The AI for adults is 550 mg/day of choline for men and 425 mg/day for women. For pregnancy and lactation, the AI is 450 mg and 550 mg daily, respectively.

Alpha-GPC

In a multicenter, randomized, placebo-controlled trial for mild cognitive impairment, subjects received 600 mg αGPC (as a soft capsule) or placebo for 12 weeks.
For Alzheimer's trials, patients have taken 400 mg three times per day (1,200 mg total).

Citicoline (CDP-Choline)

Doses range from 250–1,000 mg/day. Trials in healthy adults typically used doses of 500 mg/day, while trials in patients with neurodegenerative disease typically used doses of 1,000 mg/day.
In the citicoline + citalopram depression study cited above, people took 200 mg of citicoline daily for 6 weeks.

Choline Bitartrate

In experiments investigating the food supplement choline bitartrate for declarative and working memory in healthy young students, supplementation was tested one to two hours after administration (specific doses used were assessed acutely in the double-blind crossover design). The acute dose used in that study was not found to produce measurable cognitive benefit.

8. Safety Considerations and Drug Interactions

Tolerable Upper Intake Level

The Tolerable Upper Intake Level (UL) for choline for adults 19 years and older is 3,500 mg daily and is based on the amount that has been shown to produce adverse side effects. The critical adverse effect from high intake of choline is hypotension, with corroborative evidence on cholinergic side effects (e.g., sweating and diarrhea) and fishy body odor. The Tolerable Upper Intake Level (UL) for adults is 3.5 g/day.

Oral administration of 10 g/day of choline chloride (which is equivalent to 7.5 g [72 mmol] of choline alone) had a slight hypotensive effect in humans.

Adverse Effects at High Doses

At high dosages, gastrointestinal side effects may occur, including abdominal discomfort, diarrhea, and nausea. Fishy body odor is a reported side effect. Choline may lead to a fishy body odor in as much as 1% of the US population who have a genetic defect in the FMO3 gene, which impairs trimethylamine metabolism. A choline-restricted diet diminishes body odor in this population.

Other reported side effects at high doses include vomiting, excessive sweating and salivation, and hypotension.

Cardiovascular Safety — TMAO

The most significant safety concern with choline supplementation relates to TMAO (trimethylamine N-oxide), a compound produced when gut bacteria convert choline to TMA, which is then oxidized to TMAO in the liver. TMAO may advance atherosclerosis by reducing normal cholesterol clearing and has been associated with increased instability of atherosclerotic plaque. This concern is most prominent with forms that are readily metabolized by gut bacteria to trimethylamine, such as choline chloride or choline bitartrate. Lecithin, a choline-containing phospholipid, does not present a risk of fishy body odor because it generates little methylamine, as the bacterial enzyme cannot cleave the ester.

Prostate Cancer Risk Signal

One population study suggested an association between higher dietary choline intake and risk of lethal prostate cancer, while a later study did not find this association. Evidence is conflicting.

Drug Interactions

Choline is not known to have any clinically relevant interactions with medications according to the NIH Office of Dietary Supplements. However, some potential interactions warrant consideration: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) — choline supplements, particularly alpha-GPC and citicoline, may enhance the effects of these drugs by further increasing acetylcholine levels.

Safety of Citicoline

No serious safety issues have been reported with citicoline treatment. Citicoline is a safe and very well-tolerated form of choline with good brain bioavailability.

Populations with Special Considerations

The ULs for choline apply to healthy children and adults, but not to those taking high doses of choline under medical supervision. The Food and Nutrition Board was unable to establish ULs for infants due to the lack of data on adverse effects in this age group. The demand for choline increases particularly during pregnancy inasmuch as it is important for placental function, fetal growth, and brain development.

9. Summary of Evidence Strength

Alzheimer's disease / dementia (alpha-GPC, citicoline): Moderate evidence from multiple RCTs for slowing cognitive decline in those already diagnosed, particularly when combined with cholinesterase inhibitors. Not established as a preventive intervention.
Mild cognitive impairment (alpha-GPC): Emerging evidence from recent RCTs; statistically significant improvement on ADAS-cog at 600 mg/day.
Ischemic stroke (citicoline): Moderate clinical trial evidence for adjunct use; results across trials are mixed.
Healthy young adults (choline supplementation for cognition): No consistent benefit in controlled trials despite observational associations.
Pregnancy / neurodevelopment: Strong animal data; human interventional trials are lacking.
Liver disease related to choline deficiency: Moderate evidence for repletion benefit in clinically deficient patients (e.g., those on total parenteral nutrition).
Anxiety / depression (citicoline): Preliminary; very small studies, requires replication.
Cholinergic anti-inflammatory pathway: Well established mechanistically in preclinical models; clinical translation (e.g., in IBD, sepsis) is still under investigation.

References

Health Conditions

Health conditions that Acetylcholine may help support.

NeuroplasticityScientific
Acetylcholine is the primary neurotransmitter mediating synaptic plasticity, long-term potentiation, and hippocampal-dependent learning. Its cholinergic signaling is essential for the induction and maintenance of LTP, a cellular basis of neuroplasticity. Multiple neuroplasticity-targeting supplements work specifically by enhancing acetylcholine availability or receptor sensitivity.
Focus & ConcentrationTraditional
Acetylcholine is the primary neurotransmitter mediating attention, learning, and memory in the CNS. Its role in focus is foundational in neuropharmacology and underpins the use of numerous nootropic precursors and enzyme inhibitors. While oral supplementation with acetylcholine itself is ineffective, its role as the 'attention neurotransmitter' is supported by extensive neurophysiological and clinical evidence.

Body Systems

Body systems that Acetylcholine may help support.

No body systems available.